Genetically Modified Cells TRIZ Cases
- ABCA1-Reducing Agents for Extracellular Vesicle Secretion
Reducing ABCA1 expression or function with miR-3202 or antibodies boosts cell-derived extracellular vesicle secretion for therapeutic carriers.
- Induced Steroidogenic Cells From Pluripotent Cells for Circadian Secretion
Pluripotent cells are induced into steroidogenic cells to address slow differentiation while enabling circadian hormone production.
- Four-Gene Immortalization Preserving Antibody-Producing Cell Function
SV40 T antigen with Bcl-2, Myc, and cyclin D genes supports cell immortalization without losing antibody-producing ability.
- AT1 Cell Generation via YAP Expression and LATS Inhibition
YAP overexpression and LATS inhibition differentiate AT2 cells into AT1 cells, avoiding difficult tissue isolation for lung models.
- Anti-MUC16 Antibodies Target Retained Ectodomain After Cleavage
This case targets MUC16’s retained extracellular domain with antibody constructs for cancer diagnosis and therapy.
- Cord Blood NK Cell Expansion Using Transformed T-Cell Feeders
This culture approach uses transformed CD4+ T cells and costimulatory factors to expand cord blood NK cells for cell therapy.
- Transient Protein Expression in CHO Cells Without Medium Replenishment
A defined growth medium and enhancer composition reduce clumping while supporting up to 4 g/L recombinant protein expression in 14 days.
- Cellular Reprogramming With Transient Plasmids for Stable iPSCs
This case uses temporal plasmid expression to generate clonal iPSCs while reducing genomic changes and reversion risks.
- Modified NK Cells Overcoming Tumor Suppression in ADCC Therapy
This case uses TGFBR2 and CISH loss-of-function edits with CD16 variants to improve NK-cell survival, recognition, and ADCC.
- GBA1 Gene Correction Before Stem Cell Differentiation for DA Neurons
Correct GBA1 variants before differentiation to produce consistent therapeutic neurons.
- Antibody-Producing Cell Sorting for Non-Competitive Binding
Pre-bound competitor antibodies separate non-competitive and blocking cells for more specific enrichment and isolation.
- iPSC Microglia Differentiation via Six-Factor Transcriptional Programming
Iterative single-cell TF screening enables rapid iPSC differentiation into microglia-like cells resembling primary microglia.
- Immortalized Erythroid Progenitor Cells for Enucleated RBC Production
This case uses c-Myc and BCL-XL control in erythroid progenitors to combine sustained expansion with efficient enucleation.
- PD1-TIM3 Bispecific Antibodies for Selective T-Cell Targeting
This case combines high-affinity PD1 binding with lower-affinity TIM3 binding to restore T-cell function while limiting off-target effects.
- Stro-1+ Cell Reprogramming for Efficient, Non-Integrating iPS Production
Stro-1+ cells enable efficient iPS reprogramming with lower oncogene risk.
- Anti-DLL3 Bispecific Antibodies for Tumor-Selective Immune Activation
This case addresses DLL3's Golgi localization with antibodies that promote tumor-cell lysis and macrophage phagocytosis.
- Pluripotent Stem-Derived Treg Expansion with IL-4/TGF-β
This culture approach combines IL-4 and a TGF-βR agonist to expand pluripotent stem-derived Tregs without losing suppressive function.
- TdT Peptide Antibodies for HLA-A2-Restricted Cancer Targeting
This case uses antibodies against HLA-A2-presented TdT peptides for targeted cancer detection and treatment with fewer off-target effects.
- Hematopoietic Stem Cell Marker Selection for Predictable Engraftment
Selecting CD34+CD45RA−CD90+ HSCs creates a more homogeneous population for predictable engraftment and lower cell doses.
- Engineered Red Blood Cell Biosensors Using Bimolecular Complementation
Modular eRBC sensors reconstitute fluorescent or enzymatic signals upon ligand binding.
- Engineered T Cell Products With Controlled CD4+/CD8+ Ratios
A defined naïve-like CD4+ to CD8+ ratio guides receptor engineering for more predictable, lower-toxicity T cell products.